Molecular engineering of biotin-glutamic acid decarboxylase 65 fusion protein (Biotin-GAD65) for non-radioactive GAD65 antibody assay

Journal of Biotechnology

Volumn 103, Issue 3, 2003, Pages 249-255

  Luo, Dong ^a   Rogers, Chad N ^a   Hampe, Christiane S ^a   Lernmark, Åke ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Binding assays; Biotin; Expression; GAD65; Recombinant

Indexed keywords

ANTIBODIES; ESCHERICHIA COLI;

MOLECULAR ENGINEERING;

PROTEINS;

BIOTIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; HYBRID PROTEIN; STREPTAVIDIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING ASSAY; BIOTINYLATION; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; IMMUNOASSAY; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0142059622     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(03)00125-1     Document Type: Article

References (20)

1. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 347:1990;151-156.
2. Barker D.F., Campbell A.M. The birA gene of Escherichia coli encodes a biotin holoenzyme synthetase. J. Mol. Biol. 146:1981;451-467.
3. Barker D.F., Campbell A.M. Genetic and biochemical characterization of the birA gene and its product: evidence for a direct role of biotin holoenzyme synthetase in repression of the biotin operon in Escherichia coli. J. Mol. Biol. 146:1981;469-492.
4. Bayer E.A., Wilchek M. Biotin-binding proteins: overview and prospects. Methods Enzymol. 184:1990;49-51.
5. Bayer E.A., Wilchek M. Protein biotinylation. Methods Enzymol. 184:1990;138-160.
6. Beckett D., Kovaleva E., Schatz P.J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8:1999;921-929.
7. Cull M.G., Schatz P.J. Biotinylation of proteins in vivo and in vitro using small peptide tags. Methods Enzymol. 326:2000;430-440.
8. Giebel L.B., Cass R.T., Milligan D.L., Young D.C., Arze R., Johnson C.R. Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. Biochemistry. 34:1995;15430-15435.
9. Gitlin G., Bayer E.A., Wilchek M. Studies on the biotin-binding sites of avidin and streptavidin. Tyrosine residues are involved in the binding site. Biochem. J. 269:1990;527-530.
10. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., Karlsen A.E., Boel E., Michelsen B., Lernmark Å. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia. 37:1994;344-350.
11. Hampe C.S., Lundgren P., Daniels T.L., Hammerle L.P., Marcovina S.M., Lernmark Å. A novel monoclonal antibody specific for the N-terminal end of GAD65. J. Neuroimmunol. 113:2001;63-71.
12. Katz B.A. Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence. Biochemistry. 34:1995;15421-15429.
13. Lesley S.A., Groskreutz D.J. Simple affinity purification of antibodies using in vivo biotinylation of a fusion protein. J. Immunol. Methods. 207:1997;147-155.
14. Luo D., Geng M., Schultes B., Ma J., Xu D.Z., Hamza N., Qi W., Noujaim A.A., Madiyalakan R. Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay. J. Biotechnol. 65:1998;225-228.
15. Saggio I., Laufer R. Biotin binders selected from a random peptide library expressed on phage. Biochem. J. 293:1993;613-616.
16. Samols D., Thornton C.G., Murtif V.L., Kumar G.K., Haase F.C., Wood H.G. Evolutionary conservation among biotin enzymes. J. Biol. Chem. 263:1988;6461-6464.
17. Schatz P.J. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (New York). 11:1993;1138-1143.
18. Schranz D.B., Bekris L., Landin-Olsson M., Torn C., Nilang A., Toll A., Sjostrom J., Gronlund H., Lernmark A. Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies. Diabetes Incidence Study in Sweden (DISS). Horm. Metab. Res. 32:2000;133-138.
19. Torn C., Landin-Olsson M., Ostman J., Schersten B., Arnqvist H., Blohme G., Bjork E., Bolinder J., Eriksson J., Littorin B., Nystrom L., Sundkvist G., Lernmark A. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab. Res. Rev. 16:2000;442-447.
20. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., Chase H.P., Eisenbarth G.S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 45:1996;926-933.